 | Up a level |
Jerusalem, G; Farah, S; Courtois, A; Chirgwin, J; Aebi, S; Karlsson, P; Neven, P; Hitre, E; Graas, M P; Simoncini, E; Abdi, E; Kamby, C; Thompson, A; Loibl, S; Gavilá, J; Kuroi, K; Marth, C; Müller, B; O'Reilly, S; Gombos, A; ... (2021). Continuous versus intermittent extended adjuvant letrozole for breast cancer: final results of randomized phase III SOLE (Study of Letrozole Extension) and SOLE Estrogen Substudy. Annals of oncology, 32(10), pp. 1256-1266. Elsevier 10.1016/j.annonc.2021.07.017
Ribi, K; Aldridge, J; Phillips, K-A; Thompson, A; Harvey, V; Thürlimann, B; Cardoso, F; Pagani, O; Coates, A S; Goldhirsch, A; Price, K N; Gelber, R D; Bernhard, J (2012). Subjective cognitive complaints one year after ceasing adjuvant endocrine treatment for early-stage breast cancer. British journal of cancer, 106(10), pp. 1618-1625. Basingstoke: Nature Publishing Group 10.1038/bjc.2012.156
Karlsson, P; Sun, Z; Braun, D; Price, K N; Castiglione-Gertsch, M; Rabaglio, M; Gelber, R D; Crivellari, D; Collins, J; Murray, E; Zaman, K; Colleoni, M; Gusterson, B A; Viale, G; Regan, M M; Coates, A S; Goldhirsch, A (2011). Long-term results of International Breast Cancer Study Group Trial VIII: adjuvant chemotherapy plus goserelin compared with either therapy alone for premenopausal patients with node-negative breast cancer. Annals of oncology, 22(10), pp. 2216-26. Oxford: Oxford University Press 10.1093/annonc/mdq735
Aebi, S; Sun, Z; Braun, D; Price, K N; Castiglione-Gertsch, M; Rabaglio, M; Gelber, R D; Crivellari, D; Lindtner, J; Snyder, R; Karlsson, P; Simoncini, E; Gusterson, B A; Viale, G; Regan, M M; Coates, A S; Goldhirsch, A (2011). Differential efficacy of three cycles of CMF followed by tamoxifen in patients with ER-positive and ER-negative tumors: long-term follow up on IBCSG Trial IX. Annals of oncology, 22(9), pp. 1981-7. Oxford: Oxford University Press 10.1093/annonc/mdq754
Colleoni, M; Sun, Z; Martinelli, G; Basser, R L; Coates, A S; Gelber, R D; Green, M D; Peccatori, F; Cinieri, S; Aebi, S; Viale, G; Price, K N; Goldhirsch, A (2009). The effect of endocrine responsiveness on high-risk breast cancer treated with dose-intensive chemotherapy: results of International Breast Cancer Study Group Trial 15-95 after prolonged follow-up. Annals of oncology, 20(8), pp. 1344-51. Oxford: Oxford University Press 10.1093/annonc/mdp024
Rabaglio, M; Sun, Z; Price, K N; Castiglione-Gertsch, M; Hawle, H; Thürlimann, B; Mouridsen, H; Campone, M; Forbes, J F; Paridaens, R J; Colleoni, M; Pienkowski, T; Nogaret, J-M; Láng, I; Smith, I; Gelber, R D; Goldhirsch, A; Coates, A S (2009). Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial. Annals of oncology, 20(9), pp. 1489-98. Oxford: Oxford University Press 10.1093/annonc/mdp033
Bernhard, J; Zahrieh, D; Zhang, J J; Martinelli, G; Basser, R; Hürny, C; Forbes, J F; Aebi, S; Yeo, W; Thürlimann, B; Green, M D; Colleoni, M; Gelber, R D; Castiglione-Gertsch, M; Price, K N; Goldhirsch, A; Coates, A S (2008). Quality of life and quality-adjusted survival (Q-TWiST) in patients receiving dose-intensive or standard dose chemotherapy for high-risk primary breast cancer. British journal of cancer, 98(1), pp. 25-33. Basingstoke: Nature Publishing Group 10.1038/sj.bjc.6604092
Gruber, G; Cole, B F; Castiglione-Gertsch, M; Holmberg, S B; Lindtner, J; Golouh, R; Collins, J; Crivellari, D; Thürlimann, B; Simoncini, E; Fey, M F; Gelber, R D; Coates, A S; Price, K N; Goldhirsch, A; Viale, G; Gusterson, B A (2008). Extracapsular tumor spread and the risk of local, axillary and supraclavicular recurrence in node-positive, premenopausal patients with breast cancer. Annals of oncology, 19(8), pp. 1393-401. Oxford: Oxford University Press 10.1093/annonc/mdn123
Keshaviah, A; Dellapasqua, S; Rotmensz, N; Lindtner, J; Crivellari, D; Collins, J; Colleoni, M; Thürlimann, B; Mendiola, C; Aebi, S; Price, K N; Pagani, O; Simoncini, E; Castiglione Gertsch, M; Gelber, R D; Coates, A S; Goldhirsch, A (2007). CA15-3 and alkaline phosphatase as predictors for breast cancer recurrence: a combined analysis of seven International Breast Cancer Study Group trials. Annals of oncology, 18(4), pp. 701-8. Oxford: Oxford University Press 10.1093/annonc/mdl492
